Boundless Bio, Inc. Common Stock, par value $0.0001 per share Underwriting AgreementUnderwriting Agreement • March 21st, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations
Boundless Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.0001 per share (“Stock”), of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”
INDEMNIFICATION AND ADVANCEMENT AGREEMENTIndemnification Agreement • March 21st, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • Delaware
This Indemnification and Advancement Agreement (“Agreement”) is made as of ________ __, 20__ by and between Boundless Bio, Inc. a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/an officer/an employee/an agent] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement of expenses.
Re: Employment Offer LetterEmployment Agreement • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations
• DUTIES. You shall perform such duties as are customarily associated with the position of Chief Medical Officer, reporting into the CEO, and such other duties as are assigned to you by your supervisor. You shall perform your services on a full-time basis at the Company’s headquarters. This is an exempt position, meaning that you are not eligible for overtime compensation.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BOUNDLESS BIO, INC. April 5, 2023Investors’ Rights Agreement • September 1st, 2023 • Boundless Bio, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 5, 2023, by and among Boundless Bio, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Re: Amended and Restated Employment Offer LetterEmployment Agreement • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • California
You are currently a party to an amended and restated employment offer letter with Boundless Bio, Inc. (the “Company”) dated January 1, 2020 (the “Prior Agreement”). You and the Company hereby agree to amend and restate the Prior Agreement to memorialize the terms of your continued employment with the Company, as provided in this amended and restated employment letter agreement (this “Amended Agreement”), effective as of the date on which the Company consummates its initial public offering (“IPO”). In the event the IPO does not occur, this Amended Agreement shall not become effective and the Prior Agreement shall continue in full force and effect.
Re: Employment Offer LetterEmployment Offer Letter • September 1st, 2023 • Boundless Bio, Inc. • Pharmaceutical preparations • California
You are currently a party to an employment offer letter with Boundless Bio, Inc. (the “Company”) dated May 2, 2019 (the “Original Agreement”). You and the Company hereby agree to amend and restate the Original Agreement to enhance your severance benefits, as provided in this amended employment offer letter (this “Amended Agreement”), effective from and after January 1, 2020.
Re: Amended and Restated Employment Offer LetterEmployment Offer Letter • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • California
You are currently a party to an employment offer letter with Boundless Bio, Inc. (the “Company”) dated June 23, 2021 (the “Prior Agreement”). You and the Company hereby agree to amend and restate the Prior Agreement to memorialize the terms of your continued employment with the Company, as provided in this amended and restated employment letter agreement (this “Amended Agreement”), effective as of the date on which the Company consummates its initial public offering (“IPO”). In the event the IPO does not occur, this Amended Agreement shall not become effective and the Prior Agreement shall continue in full force and effect.
SEVERANCE AGREEMENT AND RELEASE OF ALL CLAIMSSeverance Agreement • November 7th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • New York
This Severance Agreement and Release of All Claims (“Release”) is entered into between Boundless Bio, Inc., including its officers, directors, employees, managers, agents, and representatives (“Company”), and Jamilu Rubin (“Employee”) pursuant to the Boundless Bio, Inc. Severance and Change in Control Plan (the “Plan”), effective as of the Effective Date (as defined below).
Re: Amended and Restated Employment Offer LetterEmployment Offer Letter • March 6th, 2024 • Boundless Bio, Inc. • Pharmaceutical preparations • New York
You are currently a party to an employment offer letter with Boundless Bio, Inc. (the “Company”) dated July 7, 2023 (the “Prior Agreement”). You and the Company hereby agree to amend and restate the Prior Agreement to memorialize the terms of your continued employment with the Company, as provided in this amended and restated employment letter agreement (this “Amended Agreement”), effective as of the date on which the Company consummates its initial public offering (“IPO”). In the event the IPO does not occur, this Amended Agreement shall not become effective and the Prior Agreement shall continue in full force and effect.
